NovoCure Ltd [NVCR] stock is trading at $16.89, up 1.62%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NVCR shares have gain 4.58% over the last week, with a monthly amount glided 8.06%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
NovoCure Ltd [NASDAQ: NVCR] stock has seen the most recent analyst activity on October 16, 2024, when H.C. Wainwright upgraded its rating to a Buy and also boosted its price target to $30 from $24. On August 28, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $25 on the stock. Piper Sandler upgraded its rating to a Overweight but stick to its price target of $45 on August 08, 2023. SVB Securities initiated its recommendation with a Outperform and recommended $51 as its price target on August 04, 2023. Evercore ISI upgraded its rating to In-line for this stock on July 31, 2023, but kept the price target unchanged to $33. In a note dated June 07, 2023, Wedbush upgraded an Neutral rating on this stock and revised its target price from $53 to $46.
NovoCure Ltd [NVCR] stock has fluctuated between $10.87 and $24.74 over the past year. Currently, Wall Street analysts expect the stock to reach $68.92 within the next 12 months. NovoCure Ltd [NASDAQ: NVCR] shares were valued at $16.89 at the most recent close of the market. An investor can expect a potential return of 308.05% based on the average NVCR price forecast.
Analyzing the NVCR fundamentals
NovoCure Ltd [NASDAQ:NVCR] reported sales of 549.96M for the trailing twelve months, which represents a growth of 19.28%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -0.34%, Pretax Profit Margin comes in at -0.26%, and Net Profit Margin reading is -0.31%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.46 and Total Capital is -0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.51 points at the first support level, and at 16.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.10, and for the 2nd resistance point, it is at 17.30.
Ratios To Look Out For
For context, NovoCure Ltd’s Current Ratio is 6.46. As well, the Quick Ratio is 6.22, while the Cash Ratio is 1.0. Considering the valuation of this stock, the price to sales ratio is 3.32, the price to book ratio is 5.04.
Transactions by insiders
Recent insider trading involved Cordova Ashley, Chief Financial Officer, that happened on Aug 02 ’24 when 688.0 shares were sold. Director, VERNON W ANTHONY completed a deal on Jun 04 ’24 to sell 964.0 shares. Meanwhile, Director Scannell Timothy J sold 964.0 shares on Jun 04 ’24.
